

# PAXLOVID™

(PF-07321332 tablets; ritonavir tablets)

## Registration Now Open: Pfizer Global PAXLOVID Medical Webinar!

We are delighted to invite you to attend the Pfizer Global PAXLOVID medical webinar. Please join us for an interactive session on:

### The latest data behind oral antiviral PAXLOVID: Healthcare advances in COVID-19 treatment

The webinar will be broadcast at:

**Wednesday April 6<sup>th</sup> 14:00 – 15:40 HKT (08:00 - 09:40 CEST)**

**Friday April 8<sup>th</sup> 01:00 - 02:40 HKT (April 7<sup>th</sup> 19:00 - 20:40 CEST)**

[Click here to register](#)



#### Topics will include:

- The evolving COVID-19 landscape and the increasing need for further treatment options
- The SARS-CoV-2 viral lifecycle and antiviral strategies
- An overview of PAXLOVID, including pre-clinical, Phase 1 and Phase 2/3 studies



#### Professor Patricia Muñoz

**Head, Infectious Diseases and Clinical Microbiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain**

- Professor Muñoz is a Professor in Clinical Microbiology Medicine at the Universidad Complutense de Madrid
- Her main research interests are nosocomial infections, fungal infections, infections in immunocompromised patients, infection in solid organ transplantation, infections in patients after heart surgery, infectious endocarditis, and infections in patients with acquired immunodeficiency



#### Professor Souha Kanj

**Associate Dean for Global Affairs, Head, Division of Infectious Diseases at the American University of Beirut Medical Center, Beirut, Lebanon**

- Professor Kanj is a Consulting Professor for the Division of Infectious Diseases at Duke University Medical Center
- Her research focus is in the areas of epidemiology, microbiology, and COVID-19



#### Professor Nicola Petrosillo

**Head of the Infection Prevention and Control and Infectious Disease Service at the University Hospital Campus Bio-medico, Rome, Italy**

- Professor Petrosillo is Professor of Hygiene and Infectious Diseases at the Saint Camillus University in Rome, Italy
- He is also a Researcher at Clinical Microbiology and Infection Prevention at the University Medical Center of Groningen University, The Netherlands



#### Professor Serhat Unal

**Chair, Department of Infectious Diseases, Hacettepe University, Ankara, Turkey**

- Professor Unal previously served as the Dean of the School of Medicine and Chair of the Department of Internal Medicine at Hacettepe University
- His main areas of interest are hospital infection control, antimicrobial resistance in gram positive cocci, adult vaccination, and HIV infection

**PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets) is conditionally approved by the Hong Kong Department of Health for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.**



For Healthcare Professionals only by Pfizer Hong Kong Medical

21/F., Kerry Centre, 683 King's Road, Quarry Bay, Hong Kong | Tel: +852 2811 9711 | Fax: +852 2579 0599